SHR-1906 / Jiangsu Hengrui Pharma - LARVOL DELTA

Study on Intravenous Injection of SHR-1906 in the Treatment of Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - P2 | N=30 | Completed | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Recruiting ➔ Completed | N=108 ➔ 30

Enrollment change • Trial completion • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A First-In-Human Phase 1 Study of SHR-1906, a Humanized Monoclonal Antibody Against Connective Tissue Growth Factor, in Healthy Participants. (PubMed, Clin Transl Sci) - "A single dose of SHR-1906 up to 45 mg/kg demonstrated a favorable tolerability profile in healthy participants. The pharmacokinetics and immunogenicity of SHR-1906 were evaluated, supporting further clinical development."

Clinical • Journal • P1 data • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • CTGF

Study on Intravenous Injection of SHR-1906 in the Treatment of Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - P2 | N=108 | Recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Trial of SHR - 1906 in Healthy Subjects (clinicaltrials.gov) - P1 | N=72 | Completed | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Active, not recruiting ➔ Completed

Trial completion • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Study on Intravenous Injection of SHR-1906 in the Treatment of Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - P2 | N=108 | Not yet recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

New P2 trial • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Trial of SHR - 1906 in Healthy Subjects (clinicaltrials.gov) - P1 | N=72 | Active, not recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Recruiting ➔ Active, not recruiting | Trial completion date: May 2022 ➔ Sep 2022 | Trial primary completion date: May 2022 ➔ Sep 2022

Enrollment closed • Trial completion date • Trial primary completion date • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Trial of SHR - 1906 in Healthy Subjects (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Trial of SHR - 1906 in Healthy Subjects (clinicaltrials.gov) - P1; N=48; Not yet recruiting; Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

New P1 trial • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Hengrui wins CT nods for 3 innovative candidates in China (GBI Health) - "China-based Jiangsu Hengrui Medicine Co., Ltd (600276.SH) picked up clinical trial approvals for three candidate drugs. HR17031 can now be assessed in diabetes, SHR-1701 will enter a Phase II clinical study in first-line advanced non-small cell lung cancer (NSCLC) combined with chemotherapy, and SHR-1906 will be assessed as a treatment for advanced malignant tumors."

New P2 trial • New trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology